A-71623 TFA
Names
Biological Activity
[Description]:
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively[1].
[Related Catalog]:
[Target]
IC50: 3.7 nM (CCKA receptor in radioligand binding assays)[1]
[In Vitro]
In guinea pig gastric glands, the affinities of A-71623 for the cholecystokinin (CCK)-B/gastrin receptor were 11 μM[1].
[In Vivo]
A71623 (A-63387; i.c.v., but not i.p., injections) reduces food intakes and suppresses intakes of a liquid diet in both deprived and sated rats[2]. A71623 dampens Purkinje neuron pathology and associates deficits in motor performance in Pcp2-ATXN1[30Q]D776;Cck-/- and Pcp2-AXTN1[82Q] mice[3]. A71623 improves motor performance of Pcp2-ATXN2[127Q] SCA2 mice[3]. Animal Model: Adult male, Sprague-Dawley rats[2] Dosage: 5 μL Administration: Intracerebroventricular (i.c.v) administration, A-71623 was infused using a 28 gauge injection cannula in a volume of 5uL over 60 s Result: Reduced food intakes and suppressed intakes of a liquid diet. Animal Model: ATXN1[30Q]-D776, ATXN1[82Q]-D776, ATXN2[127Q], and WT/FVB/NJ mice [3] Dosage: 0.02 mg/kg/day Administration: Osmotic minipumps containing either A71623 (0.02mg/kg/day) were implanted intraperitoneally (i.p.) Result: Treatment dampened Purkinje neuron pathology in ATXN1[30Q]D776;Cck-/- mice and ATXN1[82Q] mice. Improved motor performance in ATXN2[127Q] mice.
[References]
Chemical & Physical Properties
[ Molecular Formula ]:
C44H56N8O9
[ Molecular Weight ]:
840.96
[ Exact Mass ]:
840.41700
[ PSA ]:
254.15000
[ LogP ]:
6.24030
[ Storage condition ]:
-20°C
Precursor & DownStream
Precursor
DownStream
Related Compounds
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.